Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lantern Pharma Inc. - Common Stock (NQ:LTRN)

3.180 +0.030 (+0.95%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lantern Pharma Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
InvestorNewsBreaks – Lantern Pharma Inc. (NASDAQ: LTRN) Reports Complete Response in Advanced NSCLC Patient in HARMONIC(TM) Trial
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
Lung Cancer Patient in Lantern Pharma’s Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Inc. (NASDAQ: LTRN) Is ‘One to Watch’
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Lantern Pharma's Earnings Outlook
Via Benzinga
Preview: Lantern Pharma's Earnings
Via Benzinga
BioMedNewsBreaks — Panna Sharma, Lantern Pharma CEO, Says FDA’s Elsa AI Rollout Underscores Urgency to Modernize
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
BioMedNewsBreaks — Lantern Pharma Inc. (NASDAQ: LTRN) Highlights LP-184 Preclinical Success in Pediatric Brain Cancer ATRT
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials
From Lantern Pharma Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need
From Lantern Pharma Inc.
Via Business Wire
Earnings Scheduled For May 15, 2025
Via Benzinga
EXCLUSIVE: FDA Clears Lantern Pharma's Planned Phase 1b/2 Trial of LP-184 In Treatment-Resistant Lung Cancer Patients
Lantern Pharma receives FDA clearance to begin Phase 1b/2 trial of LP-184 in advanced NSCLC patients with key mutations and low PD-L1 expression. 
Via Benzinga
Exposures Product Safety
Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET
From Lantern Pharma Inc.
Via Business Wire
Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)
From Lantern Pharma Inc.
Via Business Wire
EXCLUSIVE: Lantern Advances Breast Cancer Drug Candidate With FDA Clearance For Early-Stage Trial
Lantern Pharma's LP-184 advances to Phase 1b/2 trial in TNBC after FDA clearance, adding to its Fast Track and Rare Pediatric Disease designations. 
Via Benzinga
Exposures Product Safety
Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
Earnings Scheduled For March 27, 2025
Via Benzinga
Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer
From Lantern Pharma Inc.
Via Business Wire
BioMedNewsBreaks — Lantern Pharma Inc. (LTRN) Expands HARMONIC™ Trial to Asia with First Patient Dosed in Taiwan
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates
From Lantern Pharma Inc.
Via Business Wire
Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board
From Lantern Pharma Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.